Additional file 4 of The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis

Wilkinson, Christel; Henderson, Robert B.; Jones-Leone, Angela R.; Flint, Shaun M.; Lennon, Mark; Levy, Roger A.; Ji, Beulah; Bass, Damon L.; Roth, David

doi:10.6084/m9.figshare.12247013.v1

13075_2020_2177_MOESM4_ESM.docx (55.03 kB)

Additional file 4 of The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis

journal contribution

posted on 2020-05-05, 03:57 authored by Christel Wilkinson, Robert B. Henderson, Angela R. Jones-Leone, Shaun M. Flint, Mark Lennon, Roger A. Levy, Beulah Ji, Damon L. Bass, David Roth

Additional file 4: Table S2. Cross tabulation of BLyS mRNA subgroups (tertiles) and IFN-1 mRNA subgroups.

Funding

GSK

History

Usage metrics

Read the peer-reviewed publication

The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis

Arthritis Research & Therapy

Keywords

Systemic lupus erythematosus B lymphocyte stimulator B cell activating factor Belimumab Interferon Messenger RNA

Licence

CC BY + CC0

Additional file 4 of The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis

Funding

GSK

History

References

Usage metrics

Read the peer-reviewed publication

Categories

Keywords

Licence

Exports